Holen Sie sich die Stockscreener-App
5.62
4.46%
0.24
Zura Bio Ltd Aktie (ZURA) Neueste Nachrichten
Zura Bio (NASDAQ:ZURA) Price Target Raised to $11.00 at Chardan Capital - Defense World
Zura Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $15.00 - Defense World
ZURA: Oppenheimer Lowers Price Target, Maintains Outperform Rati - GuruFocus
Zura Bio (NASDAQ:ZURA) Given New $15.00 Price Target at Oppenheimer - MarketBeat
Zura Bio Ltd expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Zura Bio Ltd Aktie surges on positive Phase 2 data for autoimmune drug candidate - AD HOC NEWS
Zura Bio Limited 2025 Annual Report: Clinical-Stage Biotech Advancing Novel Autoimmune Therapies and Key Risk Factors - Minichart
Zura Bio (NASDAQ: ZURA) outlines autoimmune pipeline, Phase 2 timelines - Stock Titan
Zura Bio GAAP EPS of -$1.06 misses by $0.31 - One News Page
Zura Bio 10-K: $0.0M Revenue, $(X.XX) EPS on reported net loss - TradingView
2025 financial update released as Zura Bio outlines new corporate developments - Traders Union
Zura Bio (NASDAQ: ZURA) raises cash to fund Phase 2 trials - Stock Titan
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates - ChartMill
Ajay Nirula Net Worth (2026) - GuruFocus
Boothbay Fund Management LLC Acquires New Shares in Zura Bio Limited $ZURA - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 16.2% in February - MarketBeat
Zura Bio Limited $ZURA Stock Holdings Boosted by Suvretta Capital Management LLC - MarketBeat
ZURA Technical Analysis & Stock Price Forecast - Intellectia AI
Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA - Defense World
Zura Bio’s Tibulizumab: First-in-Class Bispecific Antibody Targeting IL-17 and BAFF for Autoimmune Diseases (HS & SSc) – Pipeline, Trials, and Market Opportunity 2348 - Minichart
Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program - TipRanks
Zura Bio updates corporate presentation, flags tibulizumab Phase 2 readouts, cash and shares - TradingView
Updated investor presentation furnished by Zura Bio (NASDAQ: ZURA) - Stock Titan
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio presents Phase 2 systemic sclerosis trial design By Investing.com - Investing.com Australia
Zura Bio presents Phase 2 systemic sclerosis trial design - Investing.com South Africa
Zura Bio launches Phase 2 TibuSURE trial in systemic sclerosis at Athens congress - Traders Union
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress - weeklyvoice.com
Director at Zura Bio (ZURA) awarded 37,812 share options - Stock Titan
Major Zura Bio (ZURA) holder acquires 2M shares in registered deal - Stock Titan
Access Industries group lifts Zura Bio (ZURA) stake to 18.2% - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zura Bio heads to Miami for March 10-11 investor conferences - Stock Titan
Jessica Chen - White & Case
Zura Bio raises $144 million in public offering of shares By Investing.com - Investing.com South Africa
Zura Bio raises $144 million in public offering of shares - Investing.com India
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - ChartMill
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
Zura Bio prices $125M public offering at $6.25 per share - Investing.com Australia
Zura Bio (ZURA) launches $6.25 share and pre-funded warrant sale - Stock Titan
Zura Bio (NASDAQ: ZURA) seeks roughly $117M from 18.2M-share offering - Stock Titan
Zura Bio Prices Public Offering of 18.2 Million Shares - Intellectia AI
Zura Bio prices $125M public offering at $6.25 per share By Investing.com - Investing.com South Africa
Zura Bio launches public offering of Class A shares By Investing.com - Investing.com India
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - ChartMill
Director Mark Eisner files initial Form 3 for Zura Bio Ltd (ZURA) - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - Stock Titan
Zura Bio adds two immunology executives to board By Investing.com - Investing.com India
Zura Bio adds two immunology executives to board - Investing.com
Zura Bio (ZURA) appoints Mark Eisner and Ajay Nirula to its board - Stock Titan
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors - ChartMill
Risk Recap: What makes Zura Bio Limited stock attractive todayMarket Sentiment Report & Community Consensus Picks - baoquankhu1.vn
What risks investors should watch in Zura Bio Limited stockGDP Growth & Weekly High Momentum Picks - mfd.ru
Great Point discloses 3.8M Zura Bio (ZURA) shares in 13G/A - Stock Titan
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026 - Yahoo Finance
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 27.7% in January - MarketBeat
Why retail investors favor Zura Bio Limited stockWeekly Stock Recap & Daily Momentum Trading Reports - mfd.ru
ZURA PE Ratio & Valuation, Is ZURA Overvalued - Intellectia AI
Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases - TipRanks
Zura Bio Ltd Provides Updated Corporate Presentation - TradingView
This Nokia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Wedbush initiates coverage on Zura Bio stock with Outperform rating By Investing.com - Investing.com India
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):